Soleo Health to broaden rare disease portfolio with new exec 

FRISCO, Texas – Soleo Health has appointed Jody Thompson as senior vice president of business development, rare disease, to broaden the company’s portfolio of exclusive and limited distribution therapies for rare, ultra-rare and orphan diseases. By building key partnerships, Thompson will amplify Soleo Health’s established rare disease expertise to focus on this small, underserved population facing some of the most complex health care challenges, the company says. “Jody’s wealth of experience and leadership in successfully commercializing life-changing therapies will be instrumental as we expand our portfolio of rare and orphan therapies,” stated Drew Walk, Soleo Health CEO. “Soleo Health has been dedicated to supporting patients with rare and orphan diseases since our inception, and this strategic role underscores our ongoing commitment to our pharma, payor, provider partners and the patients we serve together.” Rare, ultra-rare and orphan diseases affect fewer than 200,000 people in the U.S., nearly half of whom are children, according to Soleo Health. Thompson joins the company with an extensive background as a pharmaceutical health care executive and a proven track record of successfully commercializing multiple rare disease products in the U.S. Prior to joining Soleo Health, she held key leadership roles in market access, patient support and huge services, with a focus on rare diseases. “I’m excited to join Soleo Health and advance its mission of delivering rare disease therapies to patients who need them most,” said Thompson. “We have an incredible opportunity to make a meaningful impact on patient care and outcomes.” 

• Related: Earlier this year, Soleo Health promoted Holly Flax to COO.